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Abstract.  Fibronectin isoforms are generated by the 
alternative splicing of a primary transcript derived 
from a  single gene.  In rat at least three regions of the 
molecule are involved: EIIIA, EIIIB, and V.  This 
study investigated the splicing patterns of these regions 
during development and aging, by means of ribonu- 
clease protection analysis. Between fetal and adult rat, 
the extent of inclusion of the EIIIA and/or EIIIB re- 
gion in fibronectin mRNA varied according to the 
type of tissue analyzed; but the inclusion of the V  re- 
gion, and in particular the V25  alternative variant, 
was significantly higher in all fetal than in adult tis- 
sues.  These data suggest a  crucial role of the V25 
variant, possibly related to its interaction with the 
c~4~1 integrin receptor during development. On the 
other hand, during aging, the only significant change 
observed in the splicing pattern was a decrease in the 
EIIIA variant in brain.  The high inclusion levels of the 
EIIIA and EIIIB regions in young adult brain suggest 
that these segments may play an important role in 
differentiated brain tissue. The decreasing levels of in- 
clusion of the EIIIA segment in brain fibronectin 
mRNA during aging may be an age-related marker 
with functional consequences. 
C 
ELL-to-cell  and cell-to-substrate interactions play a 
fundamental role in cell behavior, division, and dif- 
ferentiation.  Among the  extracellular components 
involved in these events,  fibronectin (FN) ~ is probably one 
of the most important and widely distributed. Fibronectin is 
a  dimeric  high  molecular  weight  glycoprotein  found  in 
blood, lymph, and tissue fluids, as well as in association with 
basement membranes, connective tissue matrices and the ex- 
tracellular matrix of many cells (23, 37). 
The primary structure of FN has been described at both 
protein (human and bovine FN) and cDNA (chicken, rat, 
and human FN) levels (4,  13-15, 21, 26, 32, 33, 40, 41, 43, 
45). The FN molecule is composed of three different kinds 
of repeated sequence,  known as types I, II and III with a 
characteristic modular structure (21, 33, 40, 41, 43).  These 
repeats are assembled into a  series of structural domains, 
each having a distinct binding activity toward collagen, sul- 
fated glycosaminoglycans, fibrin, and the cell surface recep- 
tors collectively termed integrins (19, 36, 49). 
FN molecules are a mixture of several protein types that 
differ both in their primary structure, and in their posttrans- 
lational modifications. All of the  sequence variations are 
produced by the alternative processing of a common mRNA 
precursor (pre-mRNA) transcribed from a single gene and 
1. Abbreviation  used in this paper:  FN, fibronectin. 
differentially spliced in the various cell types (1,  18, 30, 40, 
41, 45, 50). 
Three sites of alternative splicing have so  far been de- 
scribed: ED-A, ED-B, and IIICS in human FN and the corre- 
sponding sites (EIIIA, EIIIB, and V) in rat FN. EIIIA and 
EIIIB share a common gene structure and, in both cases, al- 
ternative splicing leads to the insertion of an additional exon 
coding for a type III homology domain. The V region in rat 
may be partially or completely excluded (depending on the 
splice site used) and may generate inserts of 0, 95, or 120 
amino acids (45). As a result of these three alternative splic- 
ing processes, 12 potential forms of rat FN canbe generated. 
The expression of various forms of FN in vivo is regulated 
in a tissue- and cell-specific fashion during development and 
wound healing, thus suggesting a possibly unique role for 
these segments (10-12, 31, 48). At least for the V25 segment, 
interaction with a specific integrin receptor on different cul- 
tured cell types have been demonstrated (20, 24). 
The extracellular matrix is known to undergo qualitative 
and quantitative changes with age (22, 27).  The importance 
of age-associated changes in cell-to-cell and cell-to-matrix 
interactions has remained relatively unexplored. In this re- 
gard, fibronectins have been considered as attractive mole- 
cules to study. Recently, in an attempt to isolate antiprolifer- 
ative mRNAs by differential hybridization from regenerating 
rat liver and early passage fibroblasts, some FN clones have 
been isolated (28).  The expression of EIIIA FNs is asso- 
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muscle cells (SMCs) (16). This phenotype is observed with 
aging (when SMCs migrate to the progressively thickening 
intima, where they proliferate and secrete extracellular ma- 
trix components), as well as in atherosclerotic lesions (16). 
Recently, the cell type-specific fashion of the alternative 
splicing of rat and human FN gene transcript has been shown 
to be a subject for modulation during transformation both in 
cultured cells and in tumors (1, 2, 5, 6). To understand the 
expression and regulation of FN variants in vivo, the pattern 
ofFN pre-mRNA splicing of the EIIIA, EIIIB and V regions 
in different rat tissues was evaluated during both develop- 
ment (from fetus to 5 mo of age) and aging (from 5 to 24 
mo of age). 
Materials and Methods 
Animals and RNA Preparation 
All of the animals were housed in specific pathogen-free facilities and fed 
ad lib. on a standard rat chow diet at the Fidia Research Laboratory (Abano 
Terme, Italy). Sprague-Dawley male rats of the following ages were used: 
17 d (fetuses; El7), and 5,  12,  17 and 24 too. Three of each age animals 
were used, with the exception of El7 and 17-too-old  rats, for which only 
two animals were studied. Rats were decapitated and their organs were im- 
mediately frozen in liquid nitrogen. Brain, liver, kidney, lung, and heart 
were obtained from rats and brain, liver, kidney, and lung from fetus. Total 
RNA was prepared from 0.5-2 g of frozen tissues homogenized in guani- 
dinium thiocyanate and ultracentrifuged in cesium-chloride gradient (7). 
Probe Preparation 
Three sets of oligonucleutide DNA primers complementary to the pub- 
lished sequence of rat fibronectin (29,  40, 45)  were synthesized using a 
DNA synthesizer (model 308A; Applied Biosystems; Foster City, CA). The 
sequences appear below. 
EIIIA1  5'-TCA  GAA CCG GAA CGG AGA AA-3' 
EIIIA2 5'-ACA AGC TTC ACG GAG GTG CTG TCT GGA GAA A-3' 
EIIIBI Y-TAT CTA GAG TCA TCC CAG AGG TGC CCC A-3' 
EIIIB2 5LTAC TGC AGT CCA GAC CTG TTT TCT G-3' 
VAR1 5'-ATA CTG CAG ACC ATC TAT GTC ATC GCA CTG AA-3' 
VAR2 5'-ACA AGC TTA GGG CTC TTC GTC AGT GCC AA-3' 
These primers spanned the EIIIA, EIIIB, and V regions ofFN mRNA plus 
a 3' 171 bp and 5' 8 bp for EIIIA, 3' 285 bp and 5' 12 bp for EHIB,  and 
3' 102 bp and 5' 67 bp for V. EIIIA2, EIIIBI, EIIIB2, VAR1, and VAR2 
primers were modified by the addition of noncomplementary bases at the 
5' ends to  create artificial recognition sites for restriction enzymes. A 
specific firsl-strand cDNA copy of the three rat FN regions was made by 
using one of the two oligonucleotide primers in each set that was com- 
plementary to the RNA strand and that served as a primer for reverse tran- 
scriptase. The synthesis of  cDNA was carried out in a 50-~1 reaction volume 
containing 10 #g of total rat heart RNA, 2.5 pmol of primer, and Moloney 
Murine Leukemia Virus reverse transcriptase (Bethesda Research Labora- 
tories, Gaithersburg, MD), used under the conditions suggested by the sup- 
plier with the omission of dactinomycin. Amplification of these first-strand 
cDNAs was performed by means ofTAQ pelymerase (Perkin-Elmer Cetus 
Corp., Norwalk, CT) according to Saiki et al. (38). 10 ~1 of the first strand 
cDNA mixture was included in a 100-/d volume with 50 pmol of each corre- 
sponding set of primers and 5 U of TAQ polymerase. 40 cycles of polymer- 
ase chain reaction (PCR) amplification were carried out, each consisting of 
1 min at 93°C, 30 s at 48°C, and 3 min at 70°C. After DNA amplification, 
the PCR mixture was digested with 15 #g of ribonuclease A at 37°C for 
30 rain and then analyzed by electrophoresis  on agarose gels. The amplified 
fragments corresponding to the EIfiA, EIIIB, and V inclusions (497, 572, 
and 544 bp, respectively) were electroeluted from the gel, subjected to re- 
striction endonuclease digestions (Psfl/Hind]II for EIIIA and V, PstI/XbaI 
for Eli]B) and subcloned in pTZ19R vector (Pharmacia, Uppsala, Sweden) 
(39). The nucleotide sequence of these clones (pTZ-A, pTZ-B, and pTZ-V) 
was identical to the previously reported rat FN sequence (29, 40, 45). 
Ribonuclease Protection Analysis 
Single-strand RNA probes, labeled with o?2P-UTP and ¢32p-CTP to a 
specific activity of 109 cpm//tg, were synthesized using a commercial tran- 
scription kit (Boehringer, Mannheim, Germany) from pTZ-A, pTZ-B, and 
pTZ-V clones linearized with EcoRI and then purified on 4% denaturing 
polyacrylamide gels (39).  The  resulting RNA probes of 499  bases for 
EIIIA, 599 bases for EIIIB and 572 bases for V had a 5' region which was 
complementary to the corresponding FN mRNA (456 bases for EIIIA, 572 
bases for EIIIB, and 529 bases for V) and the 3' bases from pTZ19R vector. 
105 cpm of single-strand RNA probe were hybridized overnight at 51°C 
with 20-40/~g of total RNA in 40 ~1 of 80% formamide, 20 mM Tris pH 
7.4, 400 mM NaCI, 1 mM EDTA and 0.1% SDS. The RNA/RNA hybrids 
were then diluted in 350 ~d of RNas¢ solution (300 mM NaC1, 5 mM EDTA, 
10 mM Tris pH 7.4, 40/Lg/ml RNase A, 3 #g/ml RNase T1) and incubated 
at 31°C  for 75  rain. 
After the addition of 30 #g of proteinase K and 20 ~1 of SDS 10%, the 
RNAs were incubated at 37°C for 15 rain, extracted with phenol and then 
EtOH precipitated. The protected fragments were analyzed on 4% denatur- 
ing polyacrylamide gels and by subsequent autoradingraphy with prdtashed 
Fuji x-ray film.  In some experiments, an artifact band that was slightly 
smaller than the intact probe was observed. This band also appeared in the 
absence of cellular RNA and must derive from probe sequences that are 
resistant to the ribonucleases under our experimental conditions. For den- 
sitometric analysis, only signals in the linear range of film sensitivity were 
used. 
The relative radioactivity of the fibonnclease-protected fragments was 
determined by means ofa Zeiss Kontron Image Analyzer 1BAS 2000 (Ober- 
kochen, Germany) and expressed as a ratio between the radioactivities of 
the upper and lower bands. Because different amounts of radiolabeled nu- 
clcotides are incorporated according to the length of the protected frag- 
ments, this ratio is not canonical, but it is an indicator of the fluctuations 
of various mRNA concentrations. 
Results 
Expression of the EIIIA Region during Development 
and Aging 
Alternative splicing at the EIIIA region generates two types 
of FN mRNA that differ in terms of  the presence of  the EIIIA 
sequence. Fig.  1 schematically shows the two FN mRNA 
variants, EIIIA+ and EIIIA-, and the sequences covered by 
the probe used to study the splicing pattern of EIIIA region 
by means of ribonuclease protection analysis. 
Total RNAs prepared from various rat tissues at El7 and 
at the different months of age were analyzed by ribonuclease 
protection assay using the EIIIA probe. Hybridization of the 
RNA probe with FN mRNAs (with and without the EI]IA 
sequence), followed by ribonuclease digestion, yielded a 456- 
base and a  171-base fragment, respectively (Figs.  1, 2, and 
3). Samples of the experimental results are shown in Figs. 2 
and 3.  Table I  summarizes the EIIIA+/EIIIA- -protected 
fragment ratio obtained by means of densitometric analysis 
of  the autoradiograms representing the average of  three inde- 
pendent experiments. 
During development, the highest EIIIA+/EIIIA-  ratio 
was found in kidney with a marked decrease from 19.80 to 
0.57 between El7 and 5 mo of age (Fig. 2, Table I). In the 
same tissue, between 5 and 24 mo of  age, the EIIIA+/EIIIA- 
ratio remained constant at '~0.5 (Table I). 
In adult liver, the EIIIA inclusion levels were very low but 
still detectable; in fetal liver it was clearly evident (Fig. 2). 
The EIIIA+/EHIA-  ratio changed from 0.14 to 0.01 be- 
tween El7  and 5  mo of age (Table  I).  During aging, the 
EIIIA+/EIIIA- ratio in liver tissue remained low (Table I). 
On the contrary, lung and brain tissues appeared to be rel- 
atively stable during ontogeny (Fig. 2). The EIIIA+/EIIIA- 
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Figure 1. (A) Schematic map of the rat fibronectin molecule. Type 
I, U, and III repeats are shown as small rectangles, ovals, and large 
rectangles,  respectively.  Binding  sites are indicated.  Alternative 
spliced exons are shown in black. (B) Schematic representation of 
the three RNA probes used in RNase protection experiments and 
the putative fragments protected with the FN mRNA variants. The 
RNA probes and their protected putative fragments are shown as 
shaded boxes and their length is indicated. The RNA probes con- 
tain extra nucleotides derived from the cloning vector at its 3' end 
(indicated by a wavy line). 
ratio changed between El7 and 5 mo of age from 1.4 to 0.66 
in lung, and from 3.9 to 3.44 in brain.  However, there was 
a marked decrease in the EIIIA+/EIIIA- ratio in brain tis- 
sue between El7 and 24 mo of age (Fig. 3), which became 
particularly acute after 12 mo when it decreased from 3.31 
to  1.23  at 24 mo. 
In heart tissue, the EIUA+/EIIIA- ratio was 0.89 in the 
adult and did not change significantly during aging (Table I). 
Expression of the EIIIB Region during Development 
and Aging 
Alternative splicing at the EII1B region generates two types 
of FN mRNA that differ in term of the presence of the EIIIB 
sequence (Fig. 1). Total RNAs prepared from various rat tis- 
sues at El7 and at the different months of age were analyzed 
by ribonuclease protection assay using the EHIB probe. Two 
protected fragments were detected:  a  572- and a  285-base 
fragment, respectively corresponding to EIIIB+ and EIIIB-. 
Samples of the experimental results are shown in Fig. 4, and 
Table I summarizes the EIIIB+/EHIB- -protected fragment 
ratio obtained by means of densitometric analysis of the au- 
toradiograms representing the average of two independent 
experiments. 
During  development, the  EIIIB+/EII1B- ratio  in liver, 
kidney and lung tissues showed a marked decrease from fetus 
to 5 mo of age. At 5 mo of age, EIIIB inclusion was undetect- 
able in liver and lung (even when the autoradiographic ex- 
posure time was increased) and was present at low levels in 
kidney. On the other hand, the EIIIB region in brain tissue 
Figure 2. Ribonuclease protection experiment examining the inclu- 
sion of  EIlIA in FN mRNA from various rat tissues during develop- 
ment. P, undigested probe; lane 1, fetal day 17; lane 2, 5 mo of age; 
lane 3, yeast tRNA. Total RNAs (20 #g for liver, lung and kidney 
and 40 #g for brain)  were hybridized  with  ct32P labeled  EIIIA 
probe, digested with ribonuclease and analyzed on 4% denaturing 
acrylamide  gel as described  in Materials  and Methods.  The pro- 
tected fragments corresponding to the inclusion (EII1A  +) or exclu- 
sion (EIIIA-) of the EIBA segment are indicated. 
was less regulated during development. In fact, in this tissue, 
the EIIIB+/EIHB- ratio was 1.80 at El7 and 0.47 at 5 mo 
of age. 
During aging, no significant changes in the ElllR+/EIIIB- 
ratio were evident in any of the tissues analyzed. 
Expression of the V Region during Development 
and Aging 
The V  region shows a  more complex pattern of alternative 
splicing than either EIIIA or EHIB and three different forms 
can be found in rat. Fig. 1 schematically shows the three FN 
mRNA variants (V1, V2, and V3) and the sequences covered 
by the probe used to study the splicing pattern of the V region 
by ribonuclease protection analysis. 
Hybridization of the RNA probe with the FN mRNAs in 
the three different forms, followed by ribonuclease digestion, 
yielded a 529-, a 387-, and a 102-base fragment, respectively 
corresponding to Vl, V2, and V3 (Fig.  1). The low intensity 
of the V3 protected band in most tissues required longer ex- 
posures before it could be visualized. This led to the linear 
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P, probe; lane 1, 5 mo of age; lane 2, 24 mo of age; lane 3, yeast tRNA. Total RNAs (20/zg for kidney, liver, and heart and 40 #g for 
brain) were hybridized with ~32P-labeled EIIIA probe, digested with ribonuclease and analyzed on 4% denaturing acrylamide gel as de- 
scribed in Materials and Methods. The protected fragments corresponding to the inclusion (+) or exclusion (-) of the EmA segment 
are indicated. 
range of film sensitivity of the higher V1 and V2 bands being 
lost.  Hence, in this study only the V1  and V2 bands were 
considered for densitometric analysis. 
Total RNAs, prepared from the various rat tissues at El7 
and at the different months of age, were analyzed by ribonu- 
clease protection assay using the V probe. Fig. 5 shows the 
different splicing patterns of  this variable region in the differ- 
ent tissues between El7 and 5 mo of age. Table I summarizes 
the V1/V2 mRNA ratio revealed by means of densitometric 
analysis of the autoradiograms obtained from ribonuclease 
protection assays, representing the average of three indepen- 
dent experiments. 
All of the tissues examined showed a marked decrease in 
the presence of the V1 form between El7 and 5 mo of age 
(Fig. 5, Table I). On the contrary, despite increased exposure 
time, no difference in band intensity was apparent for the V3 
band (data not shown). 
In adult tissues, the highest V1/V2 mRNA ratio was ob- 
served in kidney (2.71) and the lowest in liver (0.7).  During 
aging, neither the V1/V2 mRNA ratio nor the intensity of the 
V3 band changed significantly in any of the analyzed tissues. 
Discussion 
The alternative splicings of FN pre-mRNA and hence their 
possible FN isoform translations seem to be regulated by nu- 
clear trans-acting factors that in turn may be modulated by 
the environment in which the cell is present. There are two 
levels of regulation: the stable program that can be seen in 
tissue culture lines and adult organs, and the reprogramming 
induced by external agents  (growth  factors,  transforming 
agents, physical stimuli, position in the embryo, et cetera). 
The present study considered the changes occurring in FN 
pre-mRNA processing in various rat tissues during the life- 
span of the animal: after 17 d of gestation (fetal) and at 5 mo 
(the developmental period), and at 12, 17, and 24 mo (aging). 
During development (from fetus to adult age), the three al- 
ternatively spliced regions of FN have a tissue-specific regu- 
lation in which three different patterns of expression can be 
observed. The first is in kidney and liver tissues, where all 
of the three variants (EHIA, EIIIB, and V) are developmen- 
tally regulated (Figs. 2, 4, and 5; Table I). The second pat- 
tern is observed in lung, where only the EIIIB and V variants 
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and V Alternafively  Spliced Regions in Rat Tissues as 
a Function of  Age Expressed in Months 
Age (too) 
mRNA ratio  Tissue  El7  5  12  17  24 
EIIIA  +/EIIIA - 
EIIIB  +/EIIIB- 
V1/V2 
Liver  0.14  0.01  0.01  0.01  0.01 
Kidney  19.80  0.57  0.57  0.48  0.55 
Brain  3.90  3.44  3.31  2.60  1.23 
Lung  1.40  0.66  0.51  ND  ND 
Heart  ND  0.89  0.85  0.90  0.70 
Liver  0.10  <0.01  <0.01  <0.01  <0.01 
Kidney  15.00  0.03  0.03  0.05  0.04 
Brain  1.80  0.47  0.55  0.60  0.42 
Lung  1.01  <0.01  <0.01  ND  ND 
Liver  10,00  0.70  0.87  0.91  0.95 
Kidney  14.40  2.71  3.35  ND  2.50 
Brain  11.20  2.13  2.22  2.00  1.80 
Lung  15.00  1.16  1.18  ND  ND 
Heart  ND  1152  1.30  0.90  1.41 
Data obtained by densitometric  analysis of autoradiograms  deriving from ribo- 
nuclease protection experiments represent the average of three independent  ex- 
periments for the EIIIA+/EIIIA- and VI/V2 mRNA ratios and the average 
of two independent  experiments for the EIIIB  +/EIIIB- mRNA ratio. E17 = 
fetal d 17; <0.01 means that the high molecular weight protected band was un- 
detectable even when the exposure time of autoradiographic films was in- 
creased. 
show  changes,  and  where  the  EIIIA  appears  to  be  less 
closely regulated, as shown by the EIIIA+/EIIIA- mRNA 
ratio between El7 and 5 mo of age (1.40 vs. 0.66). The third 
pattern can be seen in brain, where only the V25 variant is 
developmentally regulated. In this tissue, between El7 and 
5 mo of age, the EIIIB+/EIIIB- mRNA ratio slightly de- 
creased (1.80 vs. 0.47) and the EIIIA+/EIIIA- mRNA ratio 
did not change (3.90 vs.  3.44). 
As far as the EIIIA and EfflB regions are concerned, de- 
velopmental changes in the relative inclusion of these seg- 
ments in FN mature transcripts have been previously reported 
in some human and chicken tissues (10, 11, 31).  Oyama et 
al. (37) have shown that EDA in humans is developmentally 
regulated in liver but not in lung; we observed the same thing 
in the corresponding rat tissues.  During chicken develop- 
ment, ffrench-Constant et al. (10, 11) have reported the pres- 
ence of all of the three alternatively spliced forms in early 
embryo. However, at later embryonic stages (16 d), the EIIIA 
and EIIIB regions were virtually absent in liver and in the 
other tissues, the amount of EIIIB was less than that of EI]IA 
(which was still present in large amounts at this time). In fe- 
tal rat liver, both EIIIA and EIIIB were clearly detectable in 
FN mRNA at El7 but had disappeared from the livers of 
5-mo-old rats. Both of these variants were also the predomi- 
nant forms in fetal rat kidney (Table I). In rat brain, there 
was only a slight decrease in the inclusion of the EIIIB region 
between the ages of El7 and 5  mo,  whereas there was no 
change in the EIIIA region. Some of these differences may 
be due to the species-specific timing of alternative splicing 
during fetal development. 
Changes in EIIIA and/or EIIIB inclusion have been previ- 
ously observed not only during development but also in ex- 
perimental conditions of induced FN reprogramming, such 
as wound healing (12) and the malignant transformation of 
cells (2, 5). These changes have been interpreted as indicat- 
ing that these segments (in particular the EIIIB segment) play 
Figure 4.  (A ) Ribonuclease pro- 
tection experiment examining the 
inclusion of EIIIB in FN mRNA 
from different rat tissues during 
development. P, undigested  probe; 
lane 1, fetal day 17; lane 2, 5 mo 
of age; lane 3, yeast tRNA. Total 
RNAs (20 #g for liver, lung, and 
kidney and 40 #g for brain) were 
hybridized  with  a32P-labded 
EIIIB probe, digested with ribo- 
nuclease and analyzed on 4 % de- 
naturing  acrylamide  gel  as  de- 
scribed in Materials and Methods. 
The protected  fragments  corre- 
sponding to the inclusion (EIIIB+) 
or exclusion (EIIIB-) of the EIIIB 
segment are indicated. In B, the 
same  lanes for  brain and  yeast 
tRNA exposed for a longer time. 
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tection experiment examining  the 
inclusion of the V region in FN 
mRNA from different rat tissues 
during development. P, undigested 
probe; lane 1, fetal day 17; lane 2, 
5 mo of age; lane 3, yeast tRNA. 
Total RNAs (20 #g for liver, lung, 
and kidney and 40 #g for brain) 
were hybridized  with a32P-labeled 
V probe, digested with ribonu- 
clease and analyzed on 4 % dena- 
turing acrylamide  gel as described 
in Materials and Methods. The 
protected fragments correspond- 
ing to the inclusion (VI) or exclu- 
sion (V2) of the V25 segment are 
indicated. The autoradiography, 
obtained  at  nonsaturating ex- 
posure time, do not show the V3 
protected fragment. In B, the same 
lanes for brain and yeast tRNA 
exposed for a longer time. 
a major role in the migration and/or proliferation of cells. 
However, under these experimental conditions, no different 
expression in the V region has been clearly demonstrated. 
The vast majority of previous studies did not test for a selec- 
tive specific exclusion of the V25 peptide (21, 40). The only 
study that specifically analyzes the V region in detail did not 
detect a differential expression during embryonic develop- 
ment in chicken (11), although it must be said that the alterna- 
tive splicing of FN in embryos was not compared with that 
in adult chicken tissues. Furthermore, unlike in rat, chicken 
FN at the V  region showed only two alternatively spliced 
forms (26). The V region of the chicken is only 50% homol- 
ogous with the amino acid residues of the corresponding re- 
gion in mammals, which suggests  that in avian species the 
V region may not possess a similar cell binding function. 
In our study, the V1/V2 ratio represents the presence of the 
V25 peptide in mature protein, if we assume that the mRNA 
forms correspond to the FN isoforms previously described 
(3, 35, 41, 44, 45).  This peptide can be selectively spliced 
out independently of the rest of the V region (11, 40) and is 
identical in human, rat, and cow fibronectins (34).  This re- 
gion (also called CS-1 in human FN) interacts with a specific 
integrin receptor localized on the surface of some trans- 
formed cells (20, 24). In neural avian crest cells in vitro, this 
is  the  only segment which promotes  attachment and,  in 
cooperation with the RGDS cell binding site and the synergic 
site domain of FN, it is the segment responsible for migra- 
tion (9).  The high level of inclusion of the V25 variant in all 
of  the fetal tissues analyzed suggests that it plays a major role 
during fetal development, which is possibly related to an in- 
teraction with the ot4/~l integrin receptor (20,  34). 
The alternative splicing of FN pre-mRNA was also inves- 
tigated in aging animals. Perhaps the most striking result ob- 
served was the change in FN mRNA in the EIBA region of 
the aging brain (Fig. 3, Table I). This is the first report of 
tissue-specific alterations in FN pre-mRNA processing in 
vivo during aging. The observed change in FN pre-mRNA 
alternative splicing in brain may be due to the occurrence of 
a cell specific alteration of the genetic program during aging 
(17, 42), age-related modifications in brain cell populations 
(8, 46),  or even a combination of both. 
The cell type localization of FN synthesis in the brain is 
not known. Neural avian crest cells and their derivatives do 
not synthesize FN, as detected by in situ hybridization (10, 
25), but they appear to be very responsive to surrounding FN 
and in vitro migrate on layers of the molecule (47).  On the 
contrary, rat astrocytes have been shown to synthesize FN in 
vitro (35)  and this FN includes all of the three alternative 
spliced segments (41). The high level of inclusion of EIIIA 
and EIIIB, as expressed by the corresponding mRNA ratios 
observed in adult rat brain (Table I) indicates the important 
role of these segments in differentiated  brain tissue. Previous 
studies using specific mAbs have failed to identify the EDA 
and EDB segments in adult human brain tissue (which re- 
spectively correspond to rat ElBA and EIIIB) at protein level 
(2, 5). It should be noted that overall FN expression in low 
in adult rat brain tissue and that immunohistochemical as- 
says are probably less sensitive in detecting low quantities of 
FN isoforms than RNase protection techniques. However, it 
cannot be excluded that rat and human brain tissue may be- 
have  differently in  this  respect  and  that the  alternatively 
spliced forms of FN pre-mRNA might be differently trans- 
lated  in this tissue.  To  understand the  functional role  of 
selective fibronectin changes in aging brain, we are currently 
performing further studies to examine cell localization and 
regulation of pre-mRNA alternative splicing in this tissue. 
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